1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Glioblastoma: KOL Insight

Glioblastoma: KOL Insight

  • February 2018
  • ID: 5355982
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Are novel therapies set to revolutionise glioblastoma?

There has been little progress in the treatment of glioblastoma (GBM) for decades, and management of patients continues to remain challenging. Novel treatment approaches are advancing into late-stage development, but what chances do these programmes have in reaching the market?

Learn how KOLs see the glioblastoma market evolving in Glioblastoma: KOL Insight (2018). Twelve US and European KOLs provide candid insights on 3marketed and 19 pipeline therapies targeting various aspects of the GBM disease pathophysiology

Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 6 EU & 6 US KOLs are >
• Review an extract from the report - 1 drug profile >

Top takeaways
• Is Avastin’s (Roche) future in the GBM therapeutic strategy tenable? How do oncologists view bevacizumab and will the therapy continue to be a part of the treatment regimen for GBM?
• Will Biocon’s BIOMAb EGFR reach the major US and EU markets? Phase II studies are ongoing for nimotuzumab in Cuba but how do KOLs rate its chances.
• Could anti-PD-1/CTLA-4 agents become the new standard of care with TZM for GBM patients? How do KOLs view Opdivo/Yervoy’s chances of approval in GBM?
• Could anti-PD-1/CTLA-4 agents become the new standard of care with TZM for GBM patients? How do KOLs view Opdivo/Yervoy’s chances of approval in GBM?
• Will Merck/Pfizer’s avelumab + axitinib (Inlyta) combination find a place in recurrent GBM? What do KOLs think of GliAvAx study?
• Can Medimmune (AZ)’s durvalumab/tremelimumab challenge BMS and Merck in the checkpoint inhibitor space? What potential do KOLs think anti-PD-1/CTLA-4 agents have in GBM?
• How do oncologists view the DCVax-L vaccine product and what are the chances of Tocagen’s Toca 511 gene therapy reaching the market? Will these therapies have a role in GBM?
• What questions do KOLs have regarding VBL Therapeutics’ ofranergene obadenovec (VB-111)? How do KOLs rate its chances?
• According to KOLs, what challenges does AbbVie’s ABT-414 face? Will the EGFR inhibitor have broad application?
• Can Astellas/Roche’s erlotinib + bevacizumab combination succeed in GBM? What do KOLs think of the the GLOBE study?
• Will AbbVie’s PARP inhibitor have a future in GBM? What do KOLs think of AbbVie’s veliparib, AstraZeneca’s olaparib and BeiGene’s BGB-290?
• What do KOLs think of CDK4/6 inhibitors? Will Lilly’s abemaciclib (Verzenio) reach the GBM market?
• Will p-53 pathway be ‘druggable’ in GBM? Can ONC 201 succeed where many other have failed?
• What challenges does DelMar’s VAL-083 face? Can the chemotherapy agent overcome the high hurdles and reach the market? What do KOLs say?

Quotes

“We don’t have a drug that works in GBM, so any drug that works would be great.” US Key Opinion Leader

“Clinical trials are overwhelmingly our first go-to option in the recurrent setting for glioblastoma patients. Again, we have a bunch of those that are ongoing at the moment.” US Key Opinion Leader

Sample of therapies covered

Marketed Therapies
• Avastin (Roche/Genentech)
• BIOMAb EGFR (Biocon)
• Feron (Toray/Daiichi Sankyo)

Pipeline Therapies
• Bavencio (avelumab; Merck Group)
• DCVax-L (Northwest Biotherapeutics)
• depatuxizumab mafodotin (ABT-414; AbbVie)
• dianhydrogalactitol (VAL-083; DelMar)
• veliparib (AbbVie)
• flucytosine (Toca FC; Tocagen)
• Imfinzi (durvalumab; MedImmune (AstraZeneca))
• Inlyta (axitinib; Pfizer)
• ITK 1 (BrightPath/FUJIFILM)
• Keytruda (pembrolizumab; Merck & Co.)
• ofranergene obadenovec (VB-111; VBL Therapeutics)
• ONC 201 (Oncoceutics)
• Opdivo (nivolumab; BMS/Ono Pharmaceutical)
• ribociclib (Novartis)
• Tarceva (erlotinib; Astellas/Genentech (Roche))
• Tremelimumab (MedImmune (AstraZeneca))
• Verzenio (abemaciclib; Eli Lilly)
• vocimagene amiretrorepvec (Toca 511; Tocagen)
• Yervoy (ipilimumab; BMS/Ono Pharmaceutical)

KOLs interviewed

KOLs from North America
• Anonymous KOL, MD, Professor, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
• Glenn J Lesser, MD, Professor, Hematology & Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA
• Henry S Friedman, MD, Professor of Neurosurgery; Deputy Director, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
• John H Sampson, MD, PhD, MBA, MHSc, Professor & Chief, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USAB5
• Timothy F Cloughesy, MD, Professor, Director, UCLA Neuro-Oncology Program, The Ronald Reagan UCLA Medical Center, University of California Los Angeles, CA, USA
• Tom Mikkelsen, MD, FRCPC, President and Scientific Director, Ontario Brain Institute, Toronto, ON, Canada & Co-Director, Henry Ford Health System, Henry Ford Hospital, Detroit, MI, USA

KOLs from Europe
• Andreas F Hottinger, MD, PhD, Department of Clinical Neurosciences, University Hospital Centre of Vaud, Division of Surgical Research & Gene Therapy Centre, Vaud, Switzerland
• Anthony J Chalmers, MD, Professor/Chair of Clinical Oncology, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, UK
• Carmen Balana, MD, PhD, Head of Institut Catala d’Oncologia, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
• Martin J van den Bent, MD, PhD, Professor, Head of the Neuro-Oncology Unit, Daniel den Hoed Cancer Centre, Erasmus University, Rotterdam, Netherlands
• Michael Weller, MD, PhD, Professor, University Hospital Zurich, Department of Neurology, Zurich, Switzerland
• Olivier L Chinot, MD, Professor & Head of Department, Assistance Publique Hôpitaux de Marseille, APHM, Hopital de la Timone, Marseille, France

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Schistosomiasis - Pipeline Review, H2 2019

Schistosomiasis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Schistosomiasis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Schistosomiasis - Pipeline Review, H2 2019, provides an overview of the Schistosomiasis ...

Oligodendroglioma - Pipeline Review, H2 2019

Oligodendroglioma - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Oligodendroglioma - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H2 2019, provides an overview of the Oligodendroglioma ...

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on